| abstract |
Improved antibodies are provided selected from human, dual-specific, chimeric or humanized antibodies, wherein said human chimeric and humanized antibodies specifically bind to flagellin type A or type B of P. aeruginosa , and said dual-specific antibodies specifically binds to flagella type A and type B of Pseudomonas aeruginosa , and said antibodies are protective against infection caused by P. aeruginosa . These antibodies as well as pharmaceutical composition comprising them are useful for the treatment of indications caused by P. aeruginosa infection. |